Bortezomib: all 701 studies that test it
Page 7 of 8. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.
- Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00310024Phase 1
- Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal CancerCompletedNCT00305734Phase 2
- Sorafenib and Bortezomib in Treating Patients With Advanced CancerCompletedNCT00303797Phase 1
- Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple MyelomaCompletedNCT00291538Phase 1
- Bortezomib and Celecoxib in Treating Patients With Advanced Solid TumorsCompletedNCT00290680Phase 1
- Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic MelanomaCompletedNCT00288041Phase 2
- Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell TransplantCompletedNCT00288028Phase 1
- A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung CancerTerminatedNCT00283634Phase 2
- Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal CancerCompletedNCT00280176Phase 1
- Study of Velcade and Thalidomide in Patients With MyelodysplasiaTerminatedNCT00271804Phase 1
- Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaTerminatedNCT00265928Phase 2
- Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell LymphomaStatus unknownNCT00261612Phase 2
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT00258245Phase 1
- Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and TolerabilityCompletedNCT00257114Phase 4
- Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00243035Phase 1/2
- Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast CancerCompletedNCT00237627Phase 1/2
- Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00227513Phase 1
- Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion LymphomaCompletedNCT00217503Phase 2
- An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib TherapyCompletedNCT00216697Phase 2
- VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic TherapyTerminatedNCT00210392Phase 2
- VELCADE in MALT Lymphoma Pretreated With Prior Systemic TherapyCompletedNCT00210327Phase 2
- IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple MyelomaCompletedNCT00200681Phase 3
- Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung CancerTerminatedNCT00200382Phase 2
- Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple MyelomaCompletedNCT00193557Phase 2
- Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate CancerCompletedNCT00193232Phase 2
- Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)Status unknownNCT00184015Phase 1/2
- Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT00153933Phase 1
- Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's LymphomaTerminatedNCT00148018Phase 2
- Bortezomib (Velcade) in Waldenstrom's MacroglobulinemiaCompletedNCT00142129Phase 2
- A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell LymphomaTerminatedNCT00136591Phase 2
- Study of Bortezomib Combined With ACVBP in Peripheral T-cell LymphomaCompletedNCT00136565Phase 2
- Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple MyelomaCompletedNCT00135187Not applicable
- Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With VelcadeCompletedNCT00129207Phase 1
- Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00118183Phase 2
- VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC FeaturesTerminatedNCT00117351Phase 2
- Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple MyelomaCompletedNCT00116961Phase 2
- UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory PatientsCompletedNCT00111748Phase 3
- VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple MyelomaCompletedNCT00111319Phase 3
- Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal JunctionCompletedNCT00107341Phase 2
- Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal CancerTerminatedNCT00106262Phase 2
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
- Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach CancerTerminatedNCT00103103Phase 2
- Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal CancerCompletedNCT00098982Phase 1
- Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
- Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00093769Phase 2
- Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive LymphomaTerminatedNCT00093704Phase 1
- Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy IICompletedNCT00093028Phase 3
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityActive, not recruitingNCT00092222Phase 2
- Bortezomib in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00091117Phase 1
- Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple MyelomaCompletedNCT00088855Phase 2
- VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT00085696Phase 2
- Study of Combination PS-341 and Thalidomide in Multiple MyelomaCompletedNCT00083460Phase 1
- Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00082966Phase 2
- Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
- Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple MyelomaCompletedNCT00080405Phase 1
- Bortezomib in Treating Young Patients With Refractory or Recurrent LeukemiaCompletedNCT00077467Phase 1
- Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00077441Phase 2
- Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and NeckCompletedNCT00077428Phase 2
- Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung CancerCompletedNCT00075751Phase 2
- Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaCompletedNCT00074009Phase 2
- Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaCompletedNCT00072150Phase 2
- Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00068315Phase 1
- Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyCompletedNCT00068289Phase 2
- Oxaliplatin and Bortezomib in Treating Patients With Advanced CancerTerminatedNCT00066625Phase 1
- Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To ChemotherapyCompletedNCT00066508Phase 2
- Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or UreterCompletedNCT00066352Phase 2
- Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsTerminatedNCT00064636Phase 1
- Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate CancerCompletedNCT00064610Phase 1/2
- A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039CompletedNCT00063726Phase 3
- VELCADE in Subjects With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00063713Phase 2
- Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus MitoxantroneCompletedNCT00059631Phase 1
- PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube CancerCompletedNCT00059618Phase 1
- Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
- Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal CancerCompletedNCT00052507Phase 2
- Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung CancerCompletedNCT00052338Phase 1
- Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal CarcinomaCompletedNCT00051987Phase 2
- Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00051974Phase 2
- PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00048230Phase 3
- Bortezomib in Treating Patients With Waldenstrom's MacroglobulinemiaCompletedNCT00045695Phase 2
- Bortezomib in Treating Patients With Advanced Non-small Cell Lung CancerTerminatedNCT00040768Phase 2
- Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With ChemotherapyCompletedNCT00038571Phase 2
- Bortezomib in Treating Patients With Mantle Cell LymphomaCompletedNCT00030875Phase 2
- Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT00030368Phase 1
- Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00028912Phase 1
- PS-341 in Treating Women With Metastatic Breast CancerCompletedNCT00028639Phase 2
- Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid TumorsCompletedNCT00027898Phase 1
- Bortezomib in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT00027716Phase 2
- PS-341 in Treating Women With Metastatic Breast CancerCompletedNCT00025584Phase 2
- PS-341 in Treating Patients With Metastatic Kidney CancerCompletedNCT00025376Phase 2
- PS-341 in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00024011Phase 2
- Bortezomib in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00023881Phase 2
- Bortezomib in Treating Children With Advanced Solid TumorsCompletedNCT00021216Phase 1
- PS-341 in Treating Patients With Metastatic Kidney CancerCompletedNCT00017329Phase 2
- PS-341 in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00017199Phase 2
- PS-341 and Radiation to Treat Advanced Cancer of the Head and NeckCompletedNCT00011778Phase 1
- Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00007878Phase 1
- Bortezomib in Treating Patients With Recurrent GliomaTerminatedNCT00006773Phase 1
- PS-341 in Treating Patients With Advanced CancerCompletedNCT00006362Phase 1
- PS-341 in Treating Patients With Hematologic CancerCompletedNCT00006098Phase 1
- PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic SyndromeCompletedNCT00005064Phase 1